Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U.
Lancet. 2022 Jul 23;400(10348):273-282. doi: 10.1016/S0140-6736(22)01199-0.
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H, Jia H, Xia T, Zhang D.
Dermatol Ther. 2022 Sep;35(9):e15636. doi: 10.1111/dth.15636. Epub 2022 Jul 27.
Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults.
Abduelmula A, Rankin BD, Mufti A, Yeung J, Prajapati VH.
Skin Therapy Lett. 2023 Jan;28(1):1-6.
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis.
Bernardo D, Bieber T, Torres T.
Am J Clin Dermatol. 2023 Sep;24(5):753-764. doi: 10.1007/s40257-023-00793-5. Epub 2023 Jun 2.
Treatment options for moderate to severe atopic dermatitis.
Wallace DV.
Allergy Asthma Proc. 2022 Nov 1;43(6):474-493. doi: 10.2500/aap.2022.43.220076.
Atopic Dermatitis: Diagnosis and Treatment.
Frazier W, Bhardwaj N.
Am Fam Physician. 2020 May 15;101(10):590-598.
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, Beck LA, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura MD, Chan G, Johnson S, Farooqui SA, Kerkmann U, Clibborn C.
J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2056-2066. doi: 10.1111/jdv.19280. Epub 2023 Jul 11.
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A.
Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.
The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature.
Pavel AB, Zhou L, Diaz A, Ungar B, Dan J, He H, Estrada YD, Xu H, Fernandes M, Renert-Yuval Y, Krueger JG, Guttman-Yassky E.
J Am Acad Dermatol. 2020 Mar;82(3):690-699. doi: 10.1016/j.jaad.2019.10.039. Epub 2019 Oct 25.
JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R, Paller AS.
J Allergy Clin Immunol. 2021 Oct;148(4):927-940. doi: 10.1016/j.jaci.2021.08.009. Epub 2021 Aug 24.
